LENZ Therapeutics will announce its first quarter 2026 financial results and recent corporate highlights in a webcast on May 11, 2026. The company, known for commercializing VIZZ®, the first FDA-approved eye drop for presbyopia, is expanding its global reach with ongoing licensing partnerships. LENZ management will also participate in the Bank of America Global Healthcare Conference in mid-May to engage with investors. This update is important as it reflects LENZ's progress in commercializing a novel treatment for a widespread vision condition affecting millions worldwide.
Funnel has introduced Digital Measurement, a new marketing mix modeling (MMM) software that integrates MMM, Multi-Touch Attribution (MTA), and ad platform signals into one calibrated system. This approach addresses the limitations of relying on a sin...
Zealand Pharma held an Extraordinary General Meeting on May 26, 2026, where all proposals were approved, including the election of Camilla Sylvest to the Board of Directors. The board now consists of seven shareholder-elected members and four employe...
Nvidia has been a top AI investment as demand for AI chips surged, but the next wave of IPOs from major AI customers like SpaceX, OpenAI, and Anthropic could shift investor focus. These companies, while not competitors in hardware, may compete for in...
Salazar Resources announced a new copper-gold porphyry system discovery at its 100%-owned Monja Project in southern Ecuador, featuring high-grade surface samples. This discovery comes as global copper prices hit record highs due to supply deficits, i...
Novee has introduced Agentic Fix, an enhancement to its AI penetration testing platform that automates the transition from identifying security vulnerabilities to deploying fixes. This tool generates detailed remediation guidance based on validated e...
